- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
- Laying significant foundations for marketing the NanoTherm therapy
- Completed installation of first treatment center at Charité in Berlin, Germany
- Establishing network of medical key opinion leaders
- Initial development cooperation with Mayo Clinic, USA, and distribution partnerships with DELRUS and Tek Grup (after the end of the reporting period)
- Corporate restructuring program to significantly reduce operating expenses
- Secured financing till mid-2013
Nanostart (OTCQX: NASRY)-holding MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of nanomedicine with a focus on oncology, announced the financial results for the fiscal year 2011 ending December 31, 2011.
Dr. Andreas Jordan, management and founder, commented: "2011 was a year full of major challenges for MagForce. The chosen route to market NanoTherm therapy turned out to be less successful than initially expected. We have therefore redefined our strategy and started to lay the foundations for medical community acceptance and the future commercialization of NanoTherm therapy in order to further develop the company. A new trial, which is expected to start in early 2013, will validate the benefits of NanoTherm therapy. Building confidence among leading medical experts and possible strategic partners in the therapeutic potential of our technology is of major importance. Together with strategic and distribution partners, the company will pursue further international approvals. In spring 2012, we have been reporting first progress in this regard."
After realizing the likely failure of its earlier marketing strategy, MagForce corrected the route to market for the NanoTherm therapy in a determined way. The resulting tasks will now be systematically handled by a new management team in accordance with the redefined clinical and commercial strategy. MagForce has introduced the necessary steps for establishing an extensive network of medical key opinion leaders in oncology and involving them in the further development of the technology. By convincing the leading neuro-surgeons, neuro-oncologists and radiotherapists it is expected to increase the acceptance of MagForce's technology. Additionally, the course for new scientific and commercial collaborations, the first of which were signed mid-2012, has already begun.
Results of Operations, Net Assets, and Financial Position
During the reporting period 2011, the first sales of NanoTherm therapy in the amount of TEUR 41 (previous year TEUR 0) were achieved. Net loss for the year of TEUR 8,588 (previous year TEUR 7,447) incurred during the reporting period was mainly due to increased operating expenses of TEUR 7,022 (previous year TEUR 6,464). The increase in operating expenses primarily resulted from an increase in personnel costs. This increase was mostly reversed in the second half of 2011.
The net loss was offset by income from capital increases. In 2011, the equity capital of the Company was increased from TEUR 3,917 to TEUR 4,127 by issuing new shares in return for cash contributions. Furthermore, subordination agreements were concluded for loans in the amount of TEUR 15.171. The company also received new loans from Nanostart.
Cash flow from operating activities decreased to TEUR -4,537, (previous year TEUR -5,353). Cash flow from investing activities was TEUR -1,258 (previous year TEUR -876), and cash flow from financing activities was TEUR 4,816 (previous year TEUR 6,488). As of the balance sheet date, December 31, 2011, the Company had available liquid assets totaling TEUR 14.
MagForce continues to be over-indebted as a result of the net loss for the fiscal year. However, the Company has been able to prepare a positive forecast for the successful continuation of its business. In terms of capitalization, MagForce laid the necessary foundations to secure the financing until mid-2013. Nanostart continues to back MagForce, unreservedly.
In line with the new strategy, the Company is focusing its operational activities on further validation of its technology and joint marketing with strategic partners and distributors in 2012. In cooperation with medical key opinion leaders, MagForce has designed a trial protocol for patients diagnosed with glioblastoma in order to provide further evidence for the benefits of NanoTherm therapy. The preparation for this study is expected to be completed in the second half this year. This trial will supplement the previous studies, which led to the approval of NanoTherm therapy, and will take into account the guidelines and requirements for the development of therapeutics that will complement the approval of NanoTherm therapy as a medical device.
In 2012, the Company expects a slight loss reduction compared to the previous year due to the restructuring program initiated in 2011 and planned cost-cutting activities. Not included in this assumption is a licencing agreement with a strategic partner, as expected under the new strategy.
To finance its operational activities, the Company plans further capital measures in 2012. In the first half of 2012 a total of TEUR 4,450 was raised.
The annual report 2011 is available for download on www.magforce.com.
About Nanostart AG
Nanostart AG (OTCQX: NASRY) headquartered in the German financial capital of Frankfurt, is a leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. As main shareholder of Nanostart Asia Pacific Ptd Ltd, Nanostart invests as partner of the Singaporean government.
MagForce AG is a leading medical technology company in the field of nanomedicine in oncology. The Company's proprietary, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in select countries. For more information, please visit www.magforce.com.
About NanoTherm® therapy:
The NanoTherm® therapy is a new approach for the local treatment of solid tumors. The principle of the method is the direct introduction of magnetic nanoparticles into a tumor and their subsequent heating in an alternating magnetic field. The water soluble nanoparticles are extremely small (approximately 15 nanometers in diameter), and contain an iron oxide core with an aminosilane coating. The particles are activated by a magnetic field that changes its polarity 100,000 times per second and heat is produced. Depending on the duration of treatment and the achieved intratumoral temperatures, the tumor cells are either directly destroyed (thermal ablation) or sensitized for concomitant chemo or radiotherapy (hyperthermia). With this new procedure, it is possible to combat the tumor from the inside out, thereby sparing surrounding healthy tissue. The nanoparticles remain in place at the treatment area, allowing for repeat treatments and the integration of multimodal therapy concepts. NanoTherm® therapy has regulatory approval in 27 European countries.
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan.
For more information, please click here
Dr. Hans Joachim Duerr
Head of Corporate Communications
60313 Frankfurt, Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 150
Copyright © Nanostart AGIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015
Haydale Announce Year End Results November 3rd, 2015